Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
Yamada Y, Sato K, Sakamoto S, Tsujino T, Saito S, Nishimura K, Fukushima T, Nakamura K, Yoshikawa Y, Matsunaga T, Maenosono R, Kanesaka M, Arai T, Sazuka T, Imamura Y, Komura K, Mikami K, Nakamura K, Fukasawa S, Chiba K, Naya Y, Nagata M, Komaru A, Nakatsu H, Azuma H, Ichikawa T. Yamada Y, et al. Among authors: fukushima t. Int J Clin Oncol. 2024 Dec 10. doi: 10.1007/s10147-024-02676-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39656401
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Fujimoto S, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H. Uchimoto T, et al. Among authors: fukushima t. Int J Clin Oncol. 2025 Jan;30(1):123-133. doi: 10.1007/s10147-024-02649-2. Epub 2024 Oct 28. Int J Clin Oncol. 2025. PMID: 39467994
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder Injury.
Nakamura K, Ohno T, Inamoto T, Takai T, Uchimoto T, Fukushima T, Nishimura K, Yano Y, Nishio K, Kinoshita S, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Komura K, Takahara K, Azuma H. Nakamura K, et al. Among authors: fukushima t. Oncology. 2024;102(7):1. doi: 10.1159/000535993. Epub 2023 Dec 29. Oncology. 2024. PMID: 38160665 Free PMC article.
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: fukushima t. Urol Oncol. 2022 Jul;40(7):344.e11-344.e17. doi: 10.1016/j.urolonc.2022.02.012. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346572
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Inamoto T, Sato R, Matsushita Y, Uchimoto T, Nakamura KO, Komura K, Nishimura K, Yano Y, Nishio K, Kinoshita S, Fukushima T, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Miyake H, Azuma H. Inamoto T, et al. Among authors: fukushima t. Cancer Diagn Progn. 2023 May 3;3(3):370-376. doi: 10.21873/cdp.10226. eCollection 2023 May-Jun. Cancer Diagn Progn. 2023. PMID: 37168961 Free PMC article.
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: fukushima t. Target Oncol. 2024 May;19(3):401-410. doi: 10.1007/s11523-024-01047-y. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546942
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, Ura A, Uchimoto T, Nakamura K, Fukushima T, Yano Y, Takahashi N, Nakamori K, Kinoshita S, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Hirose Y, Kimura T, Egawa S, Azuma H. Nishimura K, et al. Among authors: fukushima t. J Immunother Cancer. 2022 Jan;10(1):e003868. doi: 10.1136/jitc-2021-003868. J Immunother Cancer. 2022. PMID: 35039462 Free PMC article.
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T, Matsuda T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Tsuchida S, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: fukushima t. Target Oncol. 2024 Jul;19(4):635-644. doi: 10.1007/s11523-024-01068-7. Epub 2024 May 28. Target Oncol. 2024. PMID: 38807017
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: fukushima t. BJU Int. 2023 Apr;131(4):477-485. doi: 10.1111/bju.15893. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36098556
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
Tsujino T, Komura K, Inamoto T, Maenosono R, Hashimoto T, Adachi T, Hirasawa Y, Tokushige S, Ohno T, Yamazaki S, Fukushima T, Nakamura K, Yano Y, Nishimura K, Kinoshita S, Nakamori K, Tsutsumi T, Matsunaga T, Yoshikawa Y, Uchimoto T, Takai T, Minami K, Uehara H, Hirano H, Nomi H, Takahara K, Ohno Y, Azuma H. Tsujino T, et al. Among authors: fukushima t. World J Urol. 2023 Dec;41(12):3585-3591. doi: 10.1007/s00345-023-04687-3. Epub 2023 Nov 4. World J Urol. 2023. PMID: 37924336
2,549 results